FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn




fashion

author：leisure time    Page View：6326
Drug cost scale
Adobe

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

advertisement

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Fauci’s Covid grilling leads GOP to weigh foreign research rules
Next article： Trump demands the U.S. pay no more for drugs than other countries … again